GlobeNewswire Inc.··Sanofi And TevaSanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial
Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease